Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01965119

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma — JAK2  

Primary Mediastinal Large B-cell Lymphoma Clinical Trial

Official title:
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

Clinical Trial Summary

The purpose of this study is that ruxolitinib may be a possible treatment option for relapsed or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma.

Clinical Trial Description

Patients will take ruxolitinib 20 mg orally twice a day, 40mg in total per day, for 4 weeks.4 weeks is 1 cycle. Treatment will be continued until documented disease progression or unacceptable toxicity and the maximum period of treatment is 16 cycles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01965119
Study type Interventional
Source Samsung Medical Center
Contact
Status Completed
Phase Phase 2
Start date November 15, 2013
Completion date September 18, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04759586 - Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Phase 3
Completed NCT00532259 - CT-011 MAb in DLBCL Patients Following ASCT Phase 2
Active, not recruiting NCT00001337 - Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT03346642 - Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs Phase 1/Phase 2
Terminated NCT04358458 - First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Phase 1/Phase 2
Recruiting NCT04824950 - Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) N/A
Completed NCT01897571 - Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Phase 1/Phase 2
Completed NCT04833504 - Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
Not yet recruiting NCT06238648 - Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Phase 2
Terminated NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Withdrawn NCT02653989 - Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase 2